新闻资讯
ZonhonBio's ZHB111 Injection Receives FDA Approval for Phase I Clinical Trial
2025.06.19ON June 18, 2025, ZonhonBio announced today that the U.S. FDA has
approved its Investigational New Drug (IND) application for ZHB111
Injection, a proprietary biologic therapy developed for children with
growth retardation caused by endogenous growth hormone deficiency.
< 上一篇
没有了！
下一篇 >
没有了！